Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.


NDAQ:LEXX - Post by User

Post by lscfaon Apr 15, 2023 12:12pm
227 Views
Post# 35396681

Fins on sedar

Fins on sedar

As of February 28, 2023, the Company had cash on hand of approximately $3.3m to settle $223k in current liabilities. The Company believes this is sufficient to fund our expected R&D and operating expenditures for twelve months following the date of filing this report. We anticipate making few if any material capital expenditures in fiscal 2023 as we believe our current facilities and equipment are sufficient for the forthcoming twelve months following the date of filing this report.

 

 

$US

Revenues

Gross profit

Gross Margin

R&D

Consulting

CFO

Feb 23

35,015

32,057

91.6%

696,178

306,401

(1,264,443)

Nov 22

101,476

85,681

84.4%

829,489

321,074

(1,587,223)

Aug 22

111,150

72,641

65.4%

356,185

571,839

(711,836)

May 22

99,717

81,082

81.3%

752,095

497,962

(1,429,879)

Feb 22

30,650

24,263

79.2%

275,686

436,752

(1,170,396)

Nov 21

13,880

5,570

40.1%

458,709

738,111

(1,215,753)

Aug 21

518,683

403,326

77.8%

808,452

323,485

(1,107,843)

 

<< Previous
Bullboard Posts
Next >>